Scott L. Burrows - 03 Mar 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Chief Financial Officer
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Issuer symbol
SYRE
Transactions as of
03 Mar 2026
Net transactions value
-$65,370
Form type
4
Filing time
03 Mar 2026, 21:32:31 UTC
Previous filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Burrows Scott L Chief Financial Officer 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM /s/ Heidy King-Jones, as Attorney-in-Fact 03 Mar 2026 0001853327

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRE Common Stock Options Exercise $36,250 +2,500 +2.6% $14.50 100,494 03 Mar 2026 Direct F1
transaction SYRE Common Stock Sale $93,288 -2,300 -2.3% $40.56 98,194 03 Mar 2026 Direct F1, F2
transaction SYRE Common Stock Sale $8,332 -200 -0.2% $41.66 97,994 03 Mar 2026 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRE Stock Option (Right to Buy) Options Exercise $0 -2,500 -0.62% $0.000000 402,357 03 Mar 2026 Common Stock 2,500 $14.50 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.17 to $41.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.55 to $41.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
F5 This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.